Skip to main content

Our recent activity

Asabys Partners da entrada al FEI y eleva su primer fondo a 117 millones

PortfolioOna Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development
October 14, 2025

Ona Therapeutics, a portfolio company of Asabys Partners and Alta Life Sciences, appoints Dr. Antoine Yver as Chair of the Board to accelerate its ADC programs towards clinical development

• Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo • Led the development and approval of multiple breakthrough medicines…
PortfolioAltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys
October 2, 2025

AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys

READ THIS NEWS IN SPANISH The resulting team will manage over €400M in investments in biotechnology and medical technologies. Management of the Alta Life Sciences Spain I FCR fund will…
PortfolioAsabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®
September 10, 2025

Asabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financing to Accelerate Commercialization of Colovac®

READ THIS NEWS IN SPANISH Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise to…